The API-CAT trial: A Discussion with Isabelle Mahé, Principal Investigator

A cardiologist by training, Isabelle Mahé is Professor of Internal Medicine at Université Paris Cité. She is Head of the Internal Medicine Department at a teaching hospital (Louis Mourier, Assistance Publique Hôpitaux de Paris, Paris, France), which includes an oncology unit and a vascular disease unit. She established a tele-expertise service to help physicians manage patients with anticoagulant concerns. She is also chair of the scientific council for the INNOVTE-FCRIN Network (Investigation Network On Venous Thrombo-Embolism) and for a patients' association for anticoagulant therapy (Anticoag PASS S2D). She has broad experience in methodology and in clinical trials evaluating anticoagulants in different cardiologic or vascular indications. Her own research projects have resulted in a better management of anticoagulants in complex patients (renally impaired, elderly and cancer patients. She is leading the international prospective randomised API-CAT Study (focusing on the extended anticoagulant treatment in patients with cancer-associated thrombosis).Sebastian Szmit graduated from the Military Medical Academy in Poland (2002). From 2002 to 2012 he worked at the Military Institute of Medicine in the (1) Emergency Department, (2) Department of Internal Medicine and Cardiology, (3) Department of Oncology. From 2012 to 2022 he was employed by the Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology as cardiologist consultant of the Department of Oncology at the European Health Centre Otwock. In December 2022 he was appointed the Head of the Department of Cardio-Oncology, Centre of Postgraduate Medical Education at the Institute of Hematology and Transfusion Medicine & Consultant of the Cancer Diagnostics and Cardio-Oncology at the Maria Skłodowska-Curie National Research Institute of Oncology (Warsaw, Poland). He is cardiologist & clinical oncologist.Read the full trial results here: https://www.nejm.org/doi/full/10.1056/NEJMoa2416112

An engaging three-part podcast series designed to empower oncology nurses and advanced practice providers with the knowledge and practical tools needed to support patients with chronic lymphocytic leukemia (CLL) undergoing treatment with BTK inhibitors. Each episode brings clinical insights and evidence-based strategies to the forefront, helping nurses navigate the complexities of the BTK inhibitor therapy from both a pharmacological and patient care perspective.INSTRUCTIONS FOR PARTICIPATION AND REQUESTING CREDITThere are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the pre-test, completing the activity, and completing the post-test and evaluation form. A score of at least 50% on the posttest is required to successfully complete this activity. The participant may take the test until successfully passed.Credit Fulfillment• If you are requesting AMA credits, ANCC credits, AAPA credits, or a certificate of participation, your certificate will be available for download For credited course go to: https://www.francefoundation.com/content/9457-btki/ic-os-launch.phpThis activity is jointly provided by The France Foundation and the Internation Cardio-Oncology Society and supported by independent medical educational grants from AstraZeneca and Lilly.

An engaging three-part podcast series designed to empower oncology nurses and advanced practice providers with the knowledge and practical tools needed to support patients with chronic lymphocytic leukemia (CLL) undergoing treatment with BTK inhibitors. Each episode brings clinical insights and evidence-based strategies to the forefront, helping nurses navigate the complexities of the BTK inhibitor therapy from both a pharmacological and patient care perspective.INSTRUCTIONS FOR PARTICIPATION AND REQUESTING CREDITThere are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the pre-test, completing the activity, and completing the post-test and evaluation form. A score of at least 50% on the posttest is required to successfully complete this activity. The participant may take the test until successfully passed.Credit Fulfillment• If you are requesting AMA credits, ANCC credits, AAPA credits, or a certificate of participation, your certificate will be available for download For credited course go to: https://www.francefoundation.com/content/9457-btki/ic-os-launch.phpThis activity is jointly provided by The France Foundation and the Internation Cardio-Oncology Society and supported by independent medical educational grants from AstraZeneca and Lilly.

An engaging three-part podcast series designed to empower oncology nurses and advanced practice providers with the knowledge and practical tools needed to support patients with chronic lymphocytic leukemia (CLL) undergoing treatment with BTK inhibitors. Each episode brings clinical insights and evidence-based strategies to the forefront, helping nurses navigate the complexities of the BTK inhibitor therapy from both a pharmacological and patient care perspective.INSTRUCTIONS FOR PARTICIPATION AND REQUESTING CREDITThere are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the pre-test, completing the activity, and completing the post-test and evaluation form. A score of at least 50% on the posttest is required to successfully complete this activity. The participant may take the test until successfully passed.Credit Fulfillment• If you are requesting AMA credits, ANCC credits, AAPA credits, or a certificate of participation, your certificate will be available for download For credited course go to: https://www.francefoundation.com/content/9457-btki/ic-os-launch.phpThis activity is jointly provided by The France Foundation and the Internation Cardio-Oncology Society and supported by independent medical educational grants from AstraZeneca and Lilly.

Adina Isenberg is a cancer survivor and patient advocate who has made a lasting difference in countless lives by lobbying for legislative changes, mentoring survivors and teaching in both business and medical settings. You will be encouraged and challened by her hopeful optimism.

Dr Sara Hassing Johansen is a Researcher within the Department of Physical Performance at The Norwegian School of Sport Sciences in Oslo, Norway. Her research interests span exercise ontology, cardiorespiratory function, CPET, lung function and physiology.Read the full trial here: https://pubmed.ncbi.nlm.nih.gov/36920460/

The IC-OS Exercise Working Group published a landmark article in the European Heart Journal. "The aim of this whitepaper is to review the current state of the literature on the effects of cardio-oncology rehabilitation and exercise (CORE). There is an urgent need to reinforce and extend the evidence informing the cardiovascular care of cancer survivors." On this episode we discuss this imporchant achievement with two of the primary authors. You can read the article here: https://pubmed.ncbi.nlm.nih.gov/40036781/Dr. Erin Howden is the head of the Cardiometabolic Health and Exercise Physiology lab, co-lead of the Physical Activity Program, at the Baker Heart and Diabetes Institute, She is an honorary senior research fellow in the Department of Cardiometabolic Medicine at the University of Melbourne, Australia and chair of the IC-OS Exercise Working Group. Dr. Fernando Rivera-Theurel is a Cardiologist with specific training in Cardiovascular Prevention & Rehabilitation and Cardio-Oncology at the University of Toronto. He leads the Cardio-Oncology Rehabilitation Program at the Peter Munk Cardiac Centre and Toronto Rehabilitation Institute. He is the Co-Chair of the Exercise and Rehabilitation IC-OS working group and the Education Co-Lead of the Canadian Cardio-Oncology Network (CCON). His research is focused on the use of technology in cardiac rehab, cardio-oncology rehabilitation and cardiac rehabilitation in cardiac amyloidosis.

In the next episode, we speak with Dan Lier, best-selling author, motivational speaker, and amyloidosis survivor and advocate. Dan discusses his journey with his treating physician, Dr. Morrie Gertz from the Mayo Clinic. Both of them provide insights into the challenges of amyloidosis diagnosis, but also the hope for treatment and life after diagnosis. You won't want to miss this inspiring episode of "Heart to Heart".Learn more about Somebody to Talk To here: https://somebodytotalkto.com/View Dan's Journey on YouTube Here:https://www.youtube.com/channel/UCbSyOgziMFG_WLx7VUb5O9g

Shaden Khalaf, MD, assistant professor, MD Anderson Cancer Center, Houston, TX, USA. She specializes in cardiac imaging and its application to cardio-oncology, today we speak with her about pericardial disease in oncology patients.

Dr David Austin is a Consultant Cardiologist at The James Cook University Hospital, Middlesbrough, South Tees NHS Foundation Trust and Honorary Senior Clinical Lecturer at Newcastle University, UK.Dr Austin is founder and co-director of the Academic Cardiovascular Unit at South Tees (https://www.southtees.nhs.uk/about/strive/research-team/academic-cardiovascular-unit/) and has established grant. In this webinar he discusses The Prospective Randomized On-X Valve Anticoagulation Clinical Trial (PROACT) with special consideration for its impact on cardio-oncology care. To veiw the entire webinar go to: https://www.radcliffecardiology.com/webinars/ic-os-journal-club-proact-trial-and-reflections-cardio-protection-trials